SEP 1·SEC EDGARLow
Cancelmo Peter B sold $930K of OMER
Cancelmo Peter B (VP, General Counsel) sold 50,000 shares of OMEROS CORP (OMER) at an average of $18.59 ($18.54–$18.65, $0.93M total) across 2 trades over 2026-08-28 to 2026-08-31.
StockNASDAQ · US · USDHealthcare · Biotechnology
$OMER
OMEROS CORP
AlphAI earnings readSecond quarter of 2026 · AUG 12Omeros reported $28.5 million of second-quarter net revenue from the first full quarter of YARTEMLEA’s commercial launch, generated GAAP net income of $13.2 million, and completed debt and share repurchases in July.Verdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $OMERvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $OMER in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.7M 8 txs
HANISH ARNOLD C3× · $282K
10b5-1 share of filings25%
Top stories · $OMERMore →
AUG 28·SEC EDGAR
HANISH ARNOLD C sold $282K of OMER
HANISH ARNOLD C sold 15,000 shares of OMEROS CORP (OMER) at an average of $18.81 ($18.53–$19.02, $0.28M total) across 3 trades over 2026-08-26 to 2026-08-27.
AUG 25·investing.com
Omeros VP of finance David Borges sells $206,804 in shares
Omeros Corp's (NASDAQ:OMER) VP of Finance, David Borges, sold 10,906 shares for $206,804 after exercising options. Shares were sold at $18.95-$19.10, with options exercised at $2.94-$3.93. Omeros reported Q2 earnings of $0.02 per share, beating estimates, and revenue of $28.5M, also exceeding forecasts, driven by its drug YARTEMLEA.
OMER sentiment & insider activity
Recent OMER coverage spans insider activity, earnings and market movers.
In the last 30 days, OMER insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($1.7M). The most active reporter was HANISH ARNOLD C with 3 filings. 25% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving OMER
The insider sale may signal reduced confidence or liquidity needs, potentially pressuring the stock short-term.
Insider sale by a director may signal weak confidence, potentially pressuring the stock.
Insider sale may signal limited confidence, but size is modest for a mid‑cap biotech.
A modest insider sale by a director may signal slight concern but the amount is small relative to float.
Strong sales growth and debt reduction may boost OMER price, while positive cash flow supports further commercialization.
AlphAI scores every news story that mentions OMER with an AI model for sentiment and relevance, and aggregates insider trades from OMEROS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $OMER
Score
Cancelmo Peter B sold $930K of OMER
Cancelmo Peter B (VP, General Counsel) sold 50,000 shares of OMEROS CORP (OMER) at an average of $18.59 ($18.54–$18.65, $0.93M total) across 2 trades over 2026-08-28 to 2026-08-31.
1 min readHANISH ARNOLD C sold $282K of OMER
HANISH ARNOLD C sold 15,000 shares of OMEROS CORP (OMER) at an average of $18.81 ($18.53–$19.02, $0.28M total) across 3 trades over 2026-08-26 to 2026-08-27.
1 min readOmeros VP of finance David Borges sells $206,804 in shares
Omeros Corp's (NASDAQ:OMER) VP of Finance, David Borges, sold 10,906 shares for $206,804 after exercising options. Shares were sold at $18.95-$19.10, with options exercised at $2.94-$3.93. Omeros reported Q2 earnings of $0.02 per share, beating estimates, and revenue of $28.5M, also exceeding forecasts, driven by its drug YARTEMLEA.
2 min readCable Thomas J. sold $277K of OMER
Cable Thomas J. sold 15,000 shares of OMEROS CORP (OMER) at $18.45 ($0.28M total) on 2026-08-20.
1 min read
Omeros (OMER) Q2 2026 Earnings Call Transcript
Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.
3 min readWhy Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback
Omeros (OMER) reported Q2 2026 results moving from net losses to net income of $13.23M, and half-year net income of $69.29M. The company also completed a buyback of 843,187 shares for $9.87M under its Dec 2025 program and expanded its board to nine, adding Joseph Schocken. The article cites an ESOP-related $142.67M shelf registration and forecasts to 2029.
6 min read
Omeros Corporation Q2 2026 Earnings Call Summary
Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.
5 min readOMEROS CORP (OMER): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
OMEROS CORP (OMER) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 12, 2026, the Board of Directors of Omeros Corporation (the “Company” or “we”), upon recommendation of the Nomina
2 min readTop trending stocks today: ARX, OMER, TMS lead the market movers
Investing.com reports market movers as S&P hits a record high amid softer PPI and rate-hike bets. Accelerant Holdings surged 43.2% on an all-cash buyout by Thoma Bravo at $20.25 per share. Omeros rose 24.5% after Q2 results beat expectations, including first positive operating cash flow. Other gainers include BBB Foods and ERock.
6 min readMorning Market Movers: FGI, ARX, CLBT, HLIT See Big Swings
The article lists Thursday premarket movers, citing large early price swings in multiple stocks. Gainers include FGI Industries (FGI) up 91% to $9.24, Accelerant Holdings (ARX) up 45% to $19.67, and Harmonic (HLIT) up 23% to $14.74. Losers include Cellebrite DI (CLBT) down 28% to $11.01 and Securitize (SECZ) down 21% to $6.25.
3 min read